🇺🇸 FDA
Pipeline program

ATEZOLIZUMAB

2015/2335

Phase 2 small_molecule active

Quick answer

ATEZOLIZUMAB for Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma) is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials